Metasedin

Methadone, the active ingredient in Metasedin, is an opioid presented as an injectable solution for subcutaneous use. It is employed to manage opioid dependence by alleviating withdrawal symptoms and to provide analgesia for chronic pain in adult patients, offering a controlled and sustained effect.

GNH USA supplies Metasedin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide across multiple regions and regulatory environments with consistent quality assurance and on‑time delivery for global healthcare providers.

Methadone is used in the management of opioid‑related conditions and chronic pain. - Opioid dependence: reduces withdrawal symptoms and supports maintenance therapy in adults. - Chronic pain: provides long‑acting analgesia for severe, persistent pain. - Opioid detoxification: facilitates gradual tapering of opioid use during supervised withdrawal.

Methadone may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Constipation - Drowsiness - Sweating

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Severe hypotension

When prescribing methadone, clinicians should observe several safety measures to minimize risk. - Assess respiratory function: monitor for depression especially during initiation and dose changes. - Evaluate cardiac status: consider baseline ECG and monitor QT interval. - Avoid concurrent CNS depressants: risk of additive sedation and respiratory effects. - Use caution in hepatic impairment: methadone metabolism may be altered, requiring closer observation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methadone interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Benzodiazepines: additive respiratory depression can be life‑threatening. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase methadone plasma levels, risking toxicity. - QT‑prolonging agents (e.g., macrolide antibiotics): heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower methadone concentrations, reducing efficacy. - Alcohol: combined CNS depression may enhance sedation and respiratory effects.